Form 4: BioCardia Director Jim L. Allen Acquires 50,000 Shares in Public Offering
SEC Form 4 Filing
Director Jim L. Allen reports acquisition of 50,000 shares of BioCardia, Inc. common stock and warrants in a public offering.
Summary
- On September 3, 2024, Jim L. Allen, a director of BioCardia, Inc., acquired 50,000 shares of common stock at a price of $3 per share.
- This acquisition was part of a public offering where Allen received one share of common stock and one warrant to purchase a share of common stock for each share purchased.
- Allen also acquired 50,000 warrants, each exercisable at $3, expiring on September 3, 2029.
- Following the transaction, Allen directly owns 109,661 shares of common stock.
- Allen also indirectly owns shares held in custodial accounts for the benefit of grandchildren.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares in a public offering is generally a good sign, but it's a routine transaction.
Positives
- Director's purchase of shares in a public offering may signal confidence in the company's prospects.
- The acquisition increases Allen's direct stake in BioCardia, aligning his interests with other shareholders.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be indicative of their confidence in the company's future performance.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency in insider trading.
- Directors purchasing shares in public offerings is a common occurrence, often viewed as a positive signal.
Stakeholder Impact
- The director's purchase may increase investor confidence.
- The transaction has a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of the transaction: acquisition of shares and warrants in a public offering. |
| 09/03/2029 | Expiration date of the warrants acquired. |
| 09/05/2024 | Date of the Form 4 filing. |
| 09/30/2024 | Warrant exercisable date. |
Keywords
BioCardia, BCDA, Jim L. Allen, Director, Form 4, Public Offering, Warrants, Share Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.